ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes
June 28, 2021Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company's (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the efficacy -
America Is Losing the War Against Diabetes
June 11, 2021After years of improvement, Americans with diabetes may be losing some ground in controlling the condition, a new government-funded study shows. -
Lilly’s tirzepatide achieves superior A1C reductions versus insulin glargine
May 25, 2021Eli Lilly’s investigational candidate tirzepatide achieved superior A1C and body weight reductions compared with insulin glargine in adults with type 2 diabetes who have increased cardiovascular risk. -
Lilly's Tirzepatide Reduced A1C, Body Weight for Type 2 Diabetes
December 10, 2020Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety ... -
Keeping Blood Sugar Steady Helps You Live Longer With Diabetes
September 20, 2019Keeping your blood sugar levels stable over time may be key to living longer if you have type 2 diabetes. -
Tight Diabetes Control Alone May Not Benefit the Heart Long-Term
June 06, 2019Tight Diabetes Control Alone May Not Benefit the Heart Long-Term.
Pharma Sources Insight January 2025
